Stay updated on Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A MedlinePlus Genetics link for melanoma appears among the study’s related educational resources.
    Difference
    0.2%
    Check dated 2026-11-16T12:35:24.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The NIH site-wide announcement about the transition from “Artificial Intelligence” to “Super Intelligence” terminology is no longer displayed.
    Difference
    1%
    Check dated 2026-11-09T12:51:43.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer now identifies the site as revision v3.8.0 instead of v3.7.2, while the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T12:25:58.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition-related updates and a change in terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T11:53:19.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision marker changed from v3.7.1 to v3.7.2, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T12:48:27.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:28:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Ipilimumab Melanoma Immunotherapy Clinical Trial page.